Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(12):917; doi:10.1093/jnci/95.12.917
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Narasimhadevara, R.
Right arrow Articles by Foulkes, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Narasimhadevara, R.
Right arrow Articles by Foulkes, W. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 12, 917, June 18, 2003
© 2003 Oxford University Press

CORRESPONDENCE

Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women

Rupa Narasimhadevara, Michael N. Pollak, William D. Foulkes

Affiliations of authors: R. Narasimhadevara, Cancer Prevention Centre, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada; M. N. Pollak, Program in Cancer Prevention, McGill University, and Cancer Prevention Centre, Sir Mortimer B. Davis Jewish General Hospital; W. D. Foulkes, Program in Cancer Genetics, McGill University, and Cancer Prevention Centre, Sir Mortimer B. Davis Jewish General Hospital.

Correspondence to: William D. Foulkes, M.B. Ph.D., Cancer Prevention Centre – Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote Ste Catherine Road, Room C-107, Montreal, Quebec, Canada H3T 1E2 (e-mail: william.foulkes@mcgill.ca).

The first 10% of the full text of this article appears below.

Veronesi et al. (1) report findings from the large-scale Italian Randomized Trial of Tamoxifen. Their results show that the risk-reducing effects of tamoxifen on high-risk women with breast cancer are most marked for estrogen receptor (ER)-positive tumors. Women at high risk were defined as being . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?